Key Points
- Natera director Herm Rosenman sold 16,530 shares on June 24 at an average price of $250 each, generating about $4.13 million. After the sale, he retained 4,250 shares, a reduction of roughly 79.6% in his position.
- The transaction was filed with the SEC and was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than made on a discretionary basis.
- Natera’s stock recently traded near its 52-week high, opening at $261.91 versus a 52-week range of $131.81 to $271.47. Analysts remain generally positive, with a consensus rating of Moderate Buy and an average price target of $259.22.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Herm Rosenman sold 16,530 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director owned 4,250 shares of the company's stock, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Natera Stock Performance
Shares of NTRA stock opened at $261.91 on Friday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $271.47. The firm has a market cap of $37.51 billion, a P/E ratio of -160.68 and a beta of 1.56. The business's 50 day moving average price is $212.73 and its 200-day moving average price is $215.87.
Institutional Investors Weigh In On Natera
Hedge funds and other institutional investors have recently bought and sold shares of the business. Reflection Asset Management purchased a new position in shares of Natera during the fourth quarter valued at approximately $29,000. Palladiem LLC bought a new position in shares of Natera in the fourth quarter worth approximately $31,000. Horizon Investments LLC purchased a new stake in Natera during the 3rd quarter valued at $32,000. International Assets Investment Management LLC boosted its position in shares of Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company's stock valued at $35,000 after buying an additional 97 shares during the last quarter. Finally, Bank of Jackson Hole Trust boosted its position in shares of Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock valued at $37,000 after buying an additional 83 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. Royal Bank Of Canada initiated coverage on shares of Natera in a research report on Thursday, June 11th. They set an "outperform" rating and a $275.00 price objective on the stock. William Blair initiated coverage on shares of Natera in a research report on Tuesday, April 14th. They issued an "outperform" rating for the company. Morgan Stanley cut their target price on shares of Natera from $265.00 to $250.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 3rd. Robert W. Baird set a $265.00 price target on shares of Natera in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Natera from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $259.22.
View Our Latest Stock Analysis on Natera
About Natera
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
